Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort
Alimentary Pharmacology & Therapeutics2021Vol. 54(3), pp. 312–319
Citations Over TimeTop 10% of 2021 papers
Mathieu Uzzan, Clément Bresteau, David Laharie, Carmen Stefănescu, Christophe Bellanger, Franck Carbonnel, Mélanie Serrero, Stéphanie Viennot, Maria Nachury, Aurélien Amiot, Romain Altwegg, Laurence Picon, Stéphane Nahon, Lucine Vuitton, Philippe Ah Soune, Julien Kirchgesner, Laurent Peyrin‐Biroulet, Yoram Bouhnik, GETAID‐TALC Study Group
Abstract
Tofacitinib appears as a promising option in patients hospitalised with a UC flare but needs further validation in controlled trials.
Related Papers
- → Predicting response after infliximab salvage in acute severe ulcerative colitis(2017)51 cited
- → A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy(2019)8 cited
- → The use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis(2008)34 cited
- → PMO-252 Efficacy of infliximab therapy in acute and sub-acute ulcerative colitis(2012)3 cited
- → Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab?(2013)2 cited